﻿<?xml version="1.0" encoding="UTF-8" ?>
<rdf:RDF xmlns:admin="http://webns.net/mvcb/" xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/">
<channel rdf:about="http://medrxiv.org">
<admin:errorReportsTo rdf:resource="mailto:medrxiv@cshlpress.edu"/>
<title>medrxiv Subject Collection: Nephrology</title>
<link>http://medrxiv.org</link>
<description>
This feed contains articles for medRxiv Subject Collection "Nephrology"
</description>

<items>
<rdf:Seq>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.08.26359884v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.07.26359892v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.06.26359870v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.05.26359770v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.02.26359426v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.31.26359278v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.30.26359242v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.29.26359269v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.22.26358680v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.16.26358294v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.14.26357748v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.15.26358121v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.12.26357786v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.05.26356878v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.08.26356008v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.25.26356554v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.05.26357308v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.01.26357013v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.25.26356635v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.26.26356660v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.25.26356529v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.23.26356313v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.21.26356128v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.20.26356118v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.18.26355848v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.18.26355937v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.09.26355142v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.12.26355529v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.10.26355025v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.11.26355378v1?rss=1"/>
</rdf:Seq>
</items>
<prism:eIssn/>
<prism:publicationName>medrxiv</prism:publicationName>
<prism:issn/>

<image rdf:resource=""/>
</channel>
<image rdf:about="">
<title>medrxiv</title>
<url>https://www.medrxiv.org/sites/default/files/medrxiv_internal_logo.png</url>
<link>http://medrxiv.org</link>
</image>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.08.26359884v1?rss=1">
<title>
<![CDATA[
A-to-I RNA editing in kidney tissue from patients with nephrotic syndrome 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.08.26359884v1?rss=1
</link>
<description><![CDATA[
INTRODUCTION RNA editing has been implicated in endogenous double-stranded RNA (dsRNA) sensing and inflammatory disease, but its prevalence, genetic regulation, and consequences in diseased human kidney tissue have not been systematically characterized. Because ADAR enzymes edit multiple neighboring adenosines often in the same transcript, analyzing these sites holistically (as "clusters") may reveal effects missed by single-site analysis. METHODS We profiled both single-site and cluster A-to-I RNA editing in the kidneys of 215 participants from the Nephrotic Syndrome Study Network with focal segmental glomerulosclerosis or minimal change disease who had microdissected glomerular and/or tubulointerstitial RNA-seq and blood genome sequencing. We tested single-site and cluster editing association with estimated glomerular filtration rate, proteinuria, and an interferon stimulated gene expression score. To discover the genetic determinants of editing, we conducted mapping of both single-site, cis-editing QTL and cluster-level editing QTLs (cledQTLs). We then tested cledQTLs for colocalization with kidney eQTLs and kidney-relevant GWAS. RESULTS Greater cluster mean editing in tubulointerstitium was associated with lower interferon-stimulated gene activity (P = 4.81 x 10-9), lower UPCR (P = 0.01) and higher eGFR (P = 8.52 x 10-5). Genetic mapping identified 290 glomerular and 473 tubulointerstitial single-site edQTLs, as well as 21 glomerular and 51 tubulointerstitial cledQTLs. We identified 10 colocalized signals between cledQTL and GWAS and 14 between cledQTL and eQTL. Nine of 51 tubulointerstitial cledQTL clusters were individually associated with eGFR in NEPTUNE. CONCLUSION These results identify A-to-I RNA editing as a measurable and partly genetically regulated molecular phenotype in proteinuric kidney disease and nominate clustered editing of tubulointerstitial transcripts as a putative contributor to attenuated immune activity and higher kidney function. Cluster-level analysis identified additional genetically regulated editing patterns and colocalized signals not detected at individual sites, highlighting the added value of analyzing nearby editing sites as clusters.
]]></description>
<dc:creator><![CDATA[ Mezger, V., McNulty, M. T., Lee, D., Sampson, M. G. ]]></dc:creator>
<dc:date>2026-08-10</dc:date>
<dc:identifier>doi:10.64898/2026.08.08.26359884</dc:identifier>
<dc:title><![CDATA[A-to-I RNA editing in kidney tissue from patients with nephrotic syndrome]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-10</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.07.26359892v1?rss=1">
<title>
<![CDATA[
Genetic and environmental risk factors for intracranial aneurysm and subarachnoid haemorrhage among patients with Autosomal Dominant Polycystic Kidney Disease 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.07.26359892v1?rss=1
</link>
<description><![CDATA[
Intracranial aneurysms (IA) and their rupture (subarachnoid haemorrhage, SAH) are a rare but serious complication of autosomal dominant polycystic kidney disease (ADPKD). Both genetic and environmental risk factors contribute to the pathogenesis of IA and SAH, but specific information on risk factors in the ADPKD population are limited and international clinical guidelines mainly recommend screening for ADPKD patients with a family history of IA or SAH. We assessed the associations of monogenic variants, polygenic risk, and clinical factors with the diagnosis of IA or SAH in 2,200 adult ADPKD patients from three cohorts: the Irish Kidney Gene Project (IKGP, n=475), FinnGen (n=826), and Genomics England (GEL, n=899). Polygenic risk scores (PRS) for IA, hypertension, and smoking intensity were derived from previously published GWAS summary statistics and additionally conditioned using mtCOJO to account for their genetic correlation. IA or SAH was diagnosed in 158 of 2,200 patients (7.2%; mean age at diagnosis 51.1 years). Female sex (HR 2.21, 95% CI 1.50-3.25, p=6.52x10^-5) and smoking (HR 2.06, 95% CI 1.43-2.96, p=9.49x10^-5) were associated with IA or SAH in univariate Cox proportional hazards models, while diabetes was protective (HR 0.39, 95% CI 0.22-0.70, p=1.37x10^-3). Monogenic variant status was not found to associate with increased risk of IA or SAH. Polygenic score for IA was associated with increased risk of IA or SAH, with a 1 standard deviation increase in PRS associated with a pooled hazard ratio (HR) of 1.30 (95% CI 1.09-1.57, p=4.66x10^-3), and the association of the conditioned IA PRS remained in multivariate Cox proportional hazards models accounting for clinical factors and monogenic variants (HR 1.26, 95% CI 1.03-1.55, p=0.02). The addition of polygenic scores added significant prognostic information for IA or SAH beyond clinical risk factors in FinnGen (p=3.61x10^-3) and GEL (p=8.84x10^-3) but not in IKGP, as assessed by the likelihood ratio test. Overall, our study shows that the strongest risk factors for IA or SAH in ADPKD patients are smoking history, female sex, and polygenic risk for IA. Hypertension was not associated with IA (HR 0.50, 95% CI 0.24-1.00, p=0.051), likely due to the high prevalence of hypertension in this population across cohorts (69.6-85.3%). While family history may be considered a proxy of genetic risk, this study suggests that family history itself may be of limited utility in discriminating individuals with ADPKD at risk of IA or SAH. Keywords: Intracranial Aneurysms, subarachnoid haemorrhage, Autosomal Dominant Polycystic Kidney Disease, Polygenic Risk Scores, Hypertension, Family History
]]></description>
<dc:creator><![CDATA[ Urpa, L., Osman, S., Visser, T., Sadeghi-Alavijeh, O., shanmugam, a., fung, w., Elhassan, E. A. E., Teltsh, O., Asikainen, A., Gilbert, E. H., Cavalleri, G., Sebastian, K., Lavin, S., Rodosthenous, R., Estrada, K., Raj, R., Palotie, A., Niiranen, T., Martola, J., Korja, M., Javadpour, M., Nicholson, P., Gale, D. P., Simola, U., Finne, P., Conlon, P. J., Gordin, D. ]]></dc:creator>
<dc:date>2026-08-10</dc:date>
<dc:identifier>doi:10.64898/2026.08.07.26359892</dc:identifier>
<dc:title><![CDATA[Genetic and environmental risk factors for intracranial aneurysm and subarachnoid haemorrhage among patients with Autosomal Dominant Polycystic Kidney Disease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-10</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.06.26359870v1?rss=1">
<title>
<![CDATA[
The Urine Ammonium-pH Index is a Measure of Kidney Tubular Function 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.06.26359870v1?rss=1
</link>
<description><![CDATA[
Dysfunction of the tubulointerstitial compartment is a key driver of chronic kidney disease (CKD) progression. However, tubular function remains largely unaddressed by routine clinical assessment. Here, we show that the urine ammonium-pH index (uAPI), a composite of urinary ammonium and pH, reflects kidney tubular function and predicts kidney function decline. Using acid/base, dietary, and potassium perturbations, segmental disruption of tubular ammonium handling, mathematical modelling, and data from patients with renal tubular acidosis, we identified defective ammoniagenesis as the main uAPI determinant. The uAPI was suppressed across four kidney disease models and dissociated from GFR. Kidney proteomics and single-nucleus RNA sequencing indicated downregulation of ammoniagenesis in proteinuric and diabetic kidney disease. In type 2 diabetes patients with preserved GFR, a reduced uAPI was associated with faster kidney function decline. In three CKD cohorts, low uAPI predicted CKD progression and significantly improved risk prediction. Together, this positions the uAPI as a scalable, non-invasive measure of kidney tubular function.
]]></description>
<dc:creator><![CDATA[ Andersen, J. F., Soerensen, M. V., Chrysopoulou, M., Gullaksen, S., Nielsen, S. F., Hummelgaard, S., Ayasse, N., Jensen, I. S., Salomo, L., Simonsen, N. P., Atay, J. C., Poulsen, P. L., Noerregaard, R., Vernstroem, L., Weyer, K., Demir, F., Svendsen, S. L., Weinstein, A. M., Nielsen, S., Nielsen, M. B., Buus, N. H., Birn, H., Weiner, D. I., Rinschen, M., Leipziger, J., Berg, P. ]]></dc:creator>
<dc:date>2026-08-10</dc:date>
<dc:identifier>doi:10.64898/2026.08.06.26359870</dc:identifier>
<dc:title><![CDATA[The Urine Ammonium-pH Index is a Measure of Kidney Tubular Function]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-10</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.05.26359770v1?rss=1">
<title>
<![CDATA[
Change of prognostic nutritional index after three months of initial hemodialysis is a predictor of long-term outcomes for patients with uremia 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.05.26359770v1?rss=1
</link>
<description><![CDATA[
Nutritional status and immune function have a significant impact on the prognosis of patients undergoing maintenance hemodialysis (MHD). Previous studies have shown that the Geriatric Nutritional Risk Index (GNRI) and the Prognostic Nutritional Index (PNI) at the initiation of dialysis can be used to assess the prognosis of MHD. However, as the physical status of patients are usually unstable in the early stage of dialysis, we hypothesized that the nutritional status and immune function after a certain period of stable dialysis might be more closely related to the prognosis. This study conducted a retrospective analysis of patients who started MHD between January 1, 2019 and December 31, 2021. A total of 200 patients were included, with 66 patients succumbing during follow-up. Both initial PNI and initial GNRI exhibited a negative correlation with all-cause mortality (p=0.019 and p=0.046, respectively). After three months of MHD, both PNI and GNRI increased in most patients; however, only the PNI measured after three months was significantly associated with prognosis and higher PNI was associated with a better prognosis (p<0.001). Multivariate Cox regression analyses indicated that only PNI after three months of MHD was linked to prognosis (p=0.004). Kaplan-Meier curves demonstrated patients experiencing a decrease in PNI following three months of MHD had poorer prognoses compared to those whose PNI increased (p=0.004). Furthermore, the predictive value of PNI after three months of MHD was evident in both younger (<60 years old; p=0.024) and older (>60 years old; p=0.022) patient groups. Both the PNI and GNRI showed a downward trend before death, but only PNI had a significant decline (p=0.03, compared with PNI after three months of MHD). In conclusion, for patients undergoing MHD, the correlation between PNI and prognosis is closer than that of GNRI, and the PNI after three months of MHD is a statistically significant but moderate predictor of long-term outcomes.
]]></description>
<dc:creator><![CDATA[ Fu, S., Zhang, H., Xie, H., Wang, F., Bai, L., Zhao, F., Yang, L., Zhang, Q., Lv, M., Xue, Y., Liu, X., Gao, S., Zhang, X., xu, p., Jia, J. ]]></dc:creator>
<dc:date>2026-08-07</dc:date>
<dc:identifier>doi:10.64898/2026.08.05.26359770</dc:identifier>
<dc:title><![CDATA[Change of prognostic nutritional index after three months of initial hemodialysis is a predictor of long-term outcomes for patients with uremia]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-07</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.02.26359426v1?rss=1">
<title>
<![CDATA[
Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Medication Titration Practices in Hemodialysis Patients in the US 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.02.26359426v1?rss=1
</link>
<description><![CDATA[
Vitamin D sterols, phosphorus binders and calcimimetics are used to treat chronic kidney disease mineral and bone disorder (CKD-MBD) in hemodialysis. With few randomized trials, providers may titrate agents differently reflecting equipoise and opportunities for clinical trials. We studied patients initiating in-center hemodialysis at Dialysis Clinic, Inc facilities from 2006-2015 and who remained on hemodialysis for [&ge;]90 days (n=23,549). Multinomial logit models assessed titration among users of each medication at the start of the month considering static and dynamic CKD-MBD laboratories. Similarly parameterized logistic models assessed treatment initiation. Differences across facilities were quantified as random effects and corresponding median odds ratios. We observed patterns of titration associated with CKD-MBD laboratories including albumin-corrected serum calcium (Ca), serum phosphorus and parathyroid hormone (PTH) and minimal impact of patient characteristics. Best fit models incorporated 3 months of lagged Ca and phosphorus values and linear splines for current Ca, phosphorus and PTH values. Absolute titration probabilities for vitamin D sterols and calcimimetics were influenced by all three CKD-MBD parameters, such that Ca and phosphorus values altered the threshold PTH at which escalation and de-escalation probabilities crossed. Median odds ratios indicated the greatest facility variation for vitamin D sterol titration. Providers titrate CKD-MBD medications based largely on the full CKD-MBD laboratory phenotype, including the recent serum Ca, phosphorus and PTH history. Facility variation suggests equipoise in titration of vitamin D sterols with opportunities for clinical trials.
]]></description>
<dc:creator><![CDATA[ Scialla, J. J., Platt, A., Wilson, J., Hall, R., Ephraim, P. L., Weiner, D. E., Boulware, L. E., Pendergast, J. ]]></dc:creator>
<dc:date>2026-08-04</dc:date>
<dc:identifier>doi:10.64898/2026.08.02.26359426</dc:identifier>
<dc:title><![CDATA[Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Medication Titration Practices in Hemodialysis Patients in the US]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-04</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.31.26359278v1?rss=1">
<title>
<![CDATA[
Natural History and Post-transplant Outcomes Among Patients with Kidney Leukocyte Cell- Derived 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.31.26359278v1?rss=1
</link>
<description><![CDATA[
IntroductionALECT2 is the third most common cause of renal amyloidosis in the United States, with a strong predilection for Hispanic patients in the Southwest. (PMID:24522497) Despite its regional prevalence, data on the trajectory of kidney function decline and post-transplant outcomes remain poorly characterized.

MethodsThis is a retrospective study of patients diagnosed with ALECT2 by kidney biopsy at UNM from January 2014 to April 2024. Pre- and post-biopsy eGFR trajectories and post-transplant allograft function were analyzed.

ResultsTwelve patients had pre-biopsy data available, with a mean age at diagnosis of 64 {+/-} 12.0 years; 8 (67%) were female, and 8 identified as Hispanic. Mean eGFR at diagnosis was 31 (SD 29), indicating advanced kidney disease, with 67% diagnosed as CKD stage 4 or 5. Concomitant kidney pathology was identified in 50% of patients, with diabetic nephropathy present in two-thirds of those cases. A significant change in the eGFR trajectory was identified at the time of biopsy through change-point analysis [Figures A, C, D]. Among the four patients who underwent kidney transplantation, allograft eGFR remained stable over more than 60 months of follow-up [Figure D].

ConclusionIn this cohort of predominantly Hispanic patients, ALECT2 amyloidosis presented with advanced CKD and accelerated loss of kidney function, which prompted a biopsy that detected the disease. Post-transplant allograft function was well maintained, supporting kidney transplantation as a viable treatment strategy for ALECT2-associated kidney disease.
]]></description>
<dc:creator><![CDATA[ Munawar Ali, I. F., Lopez-Gutierrez, P. A., Iftikhar, N., Hanson, V., Afrin, S., Saelices Gomez, L., Garcia, P. R., Argyropoulos, C. P. ]]></dc:creator>
<dc:date>2026-08-03</dc:date>
<dc:identifier>doi:10.64898/2026.07.31.26359278</dc:identifier>
<dc:title><![CDATA[Natural History and Post-transplant Outcomes Among Patients with Kidney Leukocyte Cell- Derived]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-03</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.30.26359242v1?rss=1">
<title>
<![CDATA[
Non-invasive 	23Na MRI Identifies Functionally Distinct Cyst Phenotypes in Autosomal Dominant Polycystic Kidney Disease 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.30.26359242v1?rss=1
</link>
<description><![CDATA[
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by cysts from different nephron segments, yet their origin remains inaccessible to in vivo imaging. Building on ex vivo studies that cyst sodium concentration ([Na]) may reflect tubular origin, we developed a non-invasive 23Na magnetic resonance imaging (MRI) approach at 7 Tesla to phenotype ADPKD cysts in vivo based on cyst sodium. In nephrectomized ADPKD kidneys, cyst fluid [Na+] closely matched 23Na MRI signal intensities, revealing two distinct cyst phenotypes: serum-like high-[Na+] cysts and low-[Na+] cysts. High-[Na+] cysts expressed the proximal tubular marker sodium-glucose cotransporter-2, whereas low-[Na+] cysts expressed markers of distal tubules and collecting ducts. The vasopressin V2 receptor (V2R), the therapeutic target of tolvaptan, was detected exclusively in low-[Na+] cysts, linking sodium phenotype to therapeutic target expression. In vivo, {superscript 2}3Na MRI enabled classification of 2,299 cysts in 20 ADPKD patients. High-[Na+] cysts were 1.8-fold more frequent overall. Anatomical cyst localization did not predict sodium phenotype, underscoring the need for functional imaging rather than structural inference. Patients exhibited marked interindividual variation in cyst composition, with low-[Na+] cysts comprising 4.6% to 83.9% of all cysts. Given the exclusive expression of V2R in low-[Na+] cysts, this heterogeneity may influence disease progression and therapeutic responsiveness. These findings establish {superscript 2}3Na MRI as a non-invasive method to phenotype ADPKD cysts in vivo and provide a functional imaging approach with potential relevance for stratifying patients and guiding future therapeutic interventions.
]]></description>
<dc:creator><![CDATA[ Schirmer, J., Ruck, L., Dahlmann, A., Linz, P., Tkotz, K., Hoehn, J. M., Ursu, R., Kraus, A., Haerteis, S., Nuebel, B., Saake, M., Wullich, B., Schiffer, M., Uder, M., Buchholz, B., Nagel, A. M., Kopp, C. ]]></dc:creator>
<dc:date>2026-08-02</dc:date>
<dc:identifier>doi:10.64898/2026.07.30.26359242</dc:identifier>
<dc:title><![CDATA[Non-invasive 	23Na MRI Identifies Functionally Distinct Cyst Phenotypes in Autosomal Dominant Polycystic Kidney Disease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.29.26359269v1?rss=1">
<title>
<![CDATA[
Uromodulin T62P variant causes kidney tubular stress and injury modulated by age and polygenic risk 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.29.26359269v1?rss=1
</link>
<description><![CDATA[
While ultra-rare missense variants in UMOD cause highly penetrant autosomal dominant tubulointerstitial kidney disease, a more frequent UMOD T62P variant conveys intermediate risk with variable penetrance. To determine whether age or polygenic risk contributes to the variable penetrance of T62P, we combined genotype and phenotype data from 882,306 individuals across the UK Biobank (discovery cohort) and the All of Us and MyCode biobanks (validation cohorts). We also analyzed the impact of aging on uromodulin processing and cellular stress in stably transfected kidney tubular cells expressing wild-type or mutant UMOD. We compared the effects of the GPS on risk of CKD between T62P carriers and non-carriers and tested for the GPS-by-T62P interaction. The UMOD T62P variant was reproducibly associated with increased risk of CKD in an age-dependent manner. Compared to wild-type, clones of T62P-expressing cells exhibited a defective uromodulin maturation profile, causing endoplasmic reticulum retention and stress. We also observed significant T62P-by-GPS interaction, with T62P carriers in the top quintile of the GPS having over 5-fold higher risk of CKD compared to population average (OR 5.17, 95%CI: 2.94-9.08, P=1.0E-08). In summary, we demonstrate that the penetrance of kidney disease in T62P carriers is strongly modified by both age and polygenic risk.
]]></description>
<dc:creator><![CDATA[ Khan, A., Gresch, A., Olinger, E., Mariniello, M., Shang, N., Perez-Gomez, M. V., Dinsmore, I., Mabillard, H., Mirshahi, T., Chang, A. R., Devuyst, O., Kiryluk, K. ]]></dc:creator>
<dc:date>2026-07-31</dc:date>
<dc:identifier>doi:10.64898/2026.07.29.26359269</dc:identifier>
<dc:title><![CDATA[Uromodulin T62P variant causes kidney tubular stress and injury modulated by age and polygenic risk]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-31</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.22.26358680v1?rss=1">
<title>
<![CDATA[
Resolving the classification rates and molecular architecture of early-onset chronic kidney disease with NephVar 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.22.26358680v1?rss=1
</link>
<description><![CDATA[
The genetic architecture of early-onset chronic kidney disease (CKD) is caused by more than 200 monogenic genes, where their common diagnostic classes include congenital anomalies of the kidney and urinary tract, steroid-resistant nephrotic syndrome, nephronophthisis-related ciliopathies, chronic glomerulonephritis, and urinary stone disease. While advancements in whole-exome and whole-genome sequencing have enabled identification of disease-causing variants, their rates of classification have remained unknown. Likewise, the molecular effects of these pathogenic variants remain unresolved, which is essential for improving personalized treatment approaches. In this study, we collected clinical and biophysical data from 117,373 genetic variants across 129 monogenic genes causing early-onset CKD. This data established the NephVar registry, which aims to be a molecular dictionary for nephrologists to classify variants and resolve their unique molecular effects. Through NephVar, we estimated 1-15% of alleles are reclassified and the time to reclassification per variant is 2-12 years in early-onset CKD. Furthermore, NephVar identified the molecular effects of all variant types, emphasizing missense variants. Our analyses indicate that intrinsically disordered regions of proteins are protective against disease-causing missense alleles across most diagnostic classes, but often occur through a buried loss-of-function (LoF) mechanism. Additionally, we show that the mode of inheritance for these monogenic genes influences clustering patterns of genetic variants, where autosomal dominant (AD) genes are more clustered than those of autosomal recessive (AR) genes. This data accurately predicted the non-LoF effects in INF2, PAX2, GATA3, ACTN4, and LMX1B causing inherited nephrotic syndromes. We demonstrate that variant effect prediction is effective for downgrading variants of unknown significance and classifying AR genes, but challenging for pathogenic alleles in AD genes. Lastly, we propose standards and guidelines for determining non-LoF effects, including gain-of-function and dominant negative, in inherited nephrotic syndrome. Overall, the NephVar renal registry has important implications for defining the molecular architecture and estimating the progress of molecular diagnostics for early-onset CKD.
]]></description>
<dc:creator><![CDATA[ Pillai, J. P., Sayer, J. A. ]]></dc:creator>
<dc:date>2026-07-23</dc:date>
<dc:identifier>doi:10.64898/2026.07.22.26358680</dc:identifier>
<dc:title><![CDATA[Resolving the classification rates and molecular architecture of early-onset chronic kidney disease with NephVar]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-23</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.16.26358294v1?rss=1">
<title>
<![CDATA[
Switching from febuxostat to dotinurad in patients with chronic kidney disease and hyperuricemia: a single-center, non-randomized study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.16.26358294v1?rss=1
</link>
<description><![CDATA[
Recently, an observational study demonstrated that a lower fractional excretion of uric acid (FEUA) is significantly associated with a higher risk of kidney failure. This study aimed to assess the efficacy of switching from febuxostat to dotinurad, which increases FEUA, in patients with chronic kidney disease (CKD) and hyperuricemia (HUA). This was a non-randomized, open-label, single-center, prospective, single-arm study involving 60 patients with CKD and HUA who received febuxostat. Participants first underwent a 3-month observation period, followed by a 3-month intervention period, during which treatment was switched from febuxostat to dotinurad. The primary outcomes were changes from baseline to 3-months after switching in the estimated glomerular filtration rate (eGFR) calculated from serum creatinine (eGFRcreat) and serum cystatin C (eGFRcys), as well as the serum uric acid levels. The secondary outcome was defined as the correlation between {Delta}FEUA and the changes in both eGFRcreat({Delta}eGFRcreat) and eGFRcys({Delta}eGFRcys), respectively. During the observation period, mean eGFRcreat decreased significantly. The baseline eGFRcreat (mL/min/1.73 m{superscript 2}) was 36.0 {+/-} 15.2, and the serum urate level (mg/dL) was 5.5 {+/-} 1.2. During the intervention period, eGFRcreat increased in contrast to the significant decline observed in eGFRcys. After 3 months of switching to dotinurad, the mean serum UA levels increased significantly from 5.5 {+/-} 1.2 to 6.1 {+/-} 1.4 mg/dL, despite a significant elevation in FEUA. Both {Delta}eGFRcreat and {Delta}eGFRcys after switching to dotinurad were positively correlated with {Delta}FEUA. Switching from febuxostat to dotinurad resulted in discrepant changes in eGFRcreat and eGFRcys, suggesting that renal function should be assessed carefully after switch. Additionally, the risk of elevated serum UA levels should be considered when switching from febuxostat to dotinurad in patients with CKD.
]]></description>
<dc:creator><![CDATA[ Irifuku, T., Kashiwado, S., Masaki, T. ]]></dc:creator>
<dc:date>2026-07-18</dc:date>
<dc:identifier>doi:10.64898/2026.07.16.26358294</dc:identifier>
<dc:title><![CDATA[Switching from febuxostat to dotinurad in patients with chronic kidney disease and hyperuricemia: a single-center, non-randomized study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-18</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.14.26357748v1?rss=1">
<title>
<![CDATA[
Microvascular Thrombosis and Acute Kidney Injury in COVID-19: A Systematic Review and Quantitative Analysis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.14.26357748v1?rss=1
</link>
<description><![CDATA[
ObjectiveTo synthesize the available evidence on the association between SARS-CoV-2-related microvascular thrombosis and acute kidney injury (AKI), with emphasis on renal outcomes, mortality, and renal replacement therapy requirements.

MethodsThis systematic review followed the PRISMA 2020 statement and was prospectively registered in PROSPERO (CRD420251132701). PubMed/MEDLINE, Scopus, and Embase were searched for systematic reviews, including meta-analyses, and umbrella reviews investigating the association between SARS-CoV-2-related microvascular thrombosis and acute kidney injury. Two reviewers independently performed study selection, data extraction, and methodological quality assessment using AMSTAR-2 and ROBIS. Evidence was synthesized through a structured narrative synthesis supported by quantitative data extracted from the included reviews.

ResultsSix evidence syntheses evaluating kidney involvement, thrombotic events, and microvascular mechanisms in COVID-19 were included. AKI incidence was 9.2% (95%CI 4.6-13.9) among hospitalized patients and 32.6% (95%CI 8.5-56.6) among critically ill patients. In children with multisystem inflammatory syndrome associated with SARS-CoV-2, AKI incidence was 20% (95%CI 14-28). Microvascular or thrombotic events were associated with adverse renal outcomes (OR 2.14; 95%CI 1.32- 3.48). AKI was associated with increased mortality (OR 4.68; 95%CI 1.06-20.70) and greater likelihood of renal replacement therapy requirement (OR 2.87; 95%CI 1.45- 5.68). The certainty of evidence ranged from moderate to high for the principal outcomes.

ConclusionCurrent evidence supports an important association between microvascular thrombotic injury and COVID-19-associated AKI. These findings reinforce the relevance of endothelial dysfunction and thromboinflammatory pathways in kidney involvement during COVID-19 and highlight the need for early renal monitoring, risk stratification, and kidney-protective strategies in high-risk patients.
]]></description>
<dc:creator><![CDATA[ Duarte, C. A., Uscocovich, V. S. M., Misael, I., Duarte, P. D. A. C., Sestito, E. B., Da SIlva, P. N. ]]></dc:creator>
<dc:date>2026-07-17</dc:date>
<dc:identifier>doi:10.64898/2026.07.14.26357748</dc:identifier>
<dc:title><![CDATA[Microvascular Thrombosis and Acute Kidney Injury in COVID-19: A Systematic Review and Quantitative Analysis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.15.26358121v1?rss=1">
<title>
<![CDATA[
Multi-Agent Dynamic Refinement Outperforms Static RAG in Clinical Reasoning for Complex Nephrology Cases 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.15.26358121v1?rss=1
</link>
<description><![CDATA[
BackgroundLarge language models (LLMs) struggle with dynamic, longitudinal clinical reasoning. We developed a Multi-Stage Iterative Clinical Reasoning Agent framework to address this gap and systematically decouple the clinical efficacy of static retrieval-augmented generation (RAG) from dynamic self-refinement.

MethodsTen complex longitudinal nephrology cases, rigorously selected via a modified Delphi consensus technique, were blindly evaluated by four board-certified nephrologists and a multi-model AI panel. We compared three architectures across nine cognitive steps: (Model A) a baseline frontier LLM, (Model B) an LLM augmented with static guideline-based RAG, and (Model C) our proposed multi-agent framework featuring RAG integrated with iterative self-critique and refinement.

ResultsIn human evaluations (20-point scale), Model C (mean 17.2, SD 1.2) significantly outperformed both Model A (16.1, 1.3) and Model B (16.2, 1.2) (P < 0.001). Implementing static RAG (Model B) yielded no significant improvement over the baseline. Automated AI evaluations (15-point scale) corroborated these findings: Model C (14.7, 0.6) outscored Model A (14.2, 0.9, P < 0.001) and Model B (14.3, 0.9, P = 0.01). While monolithic models exhibited severe score degradations in planning-heavy tasks such as dynamic differential diagnoses, the multi-agent framework effectively intercepted error cascades, achieving significantly higher diagnostic accuracy (mean 17.6, P = 0.019) and therapeutic management scores (17.3, P = 0.002).

ConclusionsStatic knowledge retrieval alone fails to enhance frontier LLM performance in longitudinal medical reasoning. Distributing clinical workflows into a multi-agent dynamic refinement pipeline significantly improves reasoning completeness, intercepts error cascades, and safely resolves planning bottlenecks in complex patient care.
]]></description>
<dc:creator><![CDATA[ Yano, Y., Kakizaki, H., Nagasu, H., Kishi, S., Koshida, T., Nihei, Y., Hirano, A., Sugawara, Y., Imaizumi, T., Osakabe, Y., Sakaguchi, Y., Nangaku, M., Mori, H., Naito, T., Ohashi, M., Maruyama, S., Matsui, I., Isaka, Y., Okada, H., Suzuki, Y., Kashihara, N. ]]></dc:creator>
<dc:date>2026-07-16</dc:date>
<dc:identifier>doi:10.64898/2026.07.15.26358121</dc:identifier>
<dc:title><![CDATA[Multi-Agent Dynamic Refinement Outperforms Static RAG in Clinical Reasoning for Complex Nephrology Cases]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-16</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.12.26357786v1?rss=1">
<title>
<![CDATA[
From Real-World Data to Virtual Intervention: A Probabilistic Neural Network for Simulating Kidney Function Preservation via Proteinuria Reduction 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.12.26357786v1?rss=1
</link>
<description><![CDATA[
Predicting the long-term kidney function decline is critical for timely intervention but remains challenging. While the urinary protein-to-creatinine ratio (uPCR) is a potential surrogate endpoint, its short-term reductions link to long-term nephroprotection requires investigation. This study aimed to develop a probabilistic neural network model to capture both the estimated glomerular filtration rate (eGFR) slope and its uncertainty based on baseline clinical characteristics. Using a retrospective dataset, we designed a neural network to output a predictive distribution (mean  and standard deviation {sigma}) for the eGFR slope. SHAP (SHapley Additive exPlanations) was used for model interpretation, and a simulation study quantified the impact of uPCR reduction. In the validation set, the model achieved a Pearsons correlation coefficient of 0.56 and an RMSE of 2.81 ml/min/1.73m{superscript 2}/year between predicted and actual slopes. SHAP analysis identified uPCR as the most potent predictor, with higher baseline levels associated with a more rapid eGFR decline. Furthermore, a simulated 62% uPCR reduction demonstrated a significant improvement in the predicted eGFR slope, an effect most pronounced in patients with high baseline uPCR. This proof-of-concept study reinforces the critical role of uPCR in predicting eGFR slope and suggests its reduction may contribute to long-term kidney function preservation, warranting validation in larger, diverse real-world datasets.
]]></description>
<dc:creator><![CDATA[ Takeda, A., Igata, H., Mizuno, K., Yano, Y., Nagasu, H., Ohashi, M., Kashihara, N., Kobayashi, H. ]]></dc:creator>
<dc:date>2026-07-15</dc:date>
<dc:identifier>doi:10.64898/2026.07.12.26357786</dc:identifier>
<dc:title><![CDATA[From Real-World Data to Virtual Intervention: A Probabilistic Neural Network for Simulating Kidney Function Preservation via Proteinuria Reduction]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-15</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.05.26356878v1?rss=1">
<title>
<![CDATA[
Normalized barriers and unaddressed concerns: A qualitative study of the lived experiences of adults living in rural areas with advanced chronic kidney disease 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.05.26356878v1?rss=1
</link>
<description><![CDATA[
Rationale & ObjectivePeople who live in rural areas with advanced chronic kidney disease (CKD) face well-documented structural barriers to receiving care, yet little is known about how they experience their illness or perceive interactions with their healthcare teams. We aimed to characterize the lived experiences and care perceptions of adults living in rural areas with advanced, pre-dialysis CKD.

Study DesignWe conducted semi-structured qualitative interviews with patients and care partners.

Setting & ParticipantsWe recruited patients with advanced CKD (stages 4-5, not on dialysis) and their care partners from a single hospital-based nephrology clinic in northern New England serving a predominantly rural population.

Analytical ApproachWe analyzed interview transcripts using participatory Practical Thematic Analysis (PTA), an inductive, stakeholder-engaged approach to qualitative analysis.

ResultsWe interviewed 12 patients and 4 care partners. Four themes were identified: (1) logistical challenges of rural CKD care were pervasive but frequently normalized as an expected feature of rural life; (2) disease progression and future treatments were sources of uncertainty and concern, with expectations about dialysis often shaped by peer accounts rather than clinical discussion; (3) clinical conversations centered on laboratory results and medications, leaving emotional concerns and psychologic challenges unaddressed; and (4) physical symptoms and lifestyle changes were common but frequently attributed to comorbid conditions rather than to CKD.

LimitationsRecruitment from a single clinic with a small, racially homogeneous sample limits transferability. While in-person recruitment may have excluded patients with greater transportation barriers, those who attended represent a population navigating substantial access challenges to receive care.

ConclusionsAdults living in rural areas with advanced CKD experience logistical, emotional, and informational challenges broadly consistent with those reported in non-rural CKD populations. Patients normalized geographic barriers and did not consistently identify rurality as a source of disadvantage, even as structural barriers persisted. These findings support the development of structured communication approaches in nephrology care that invite discussion of disease trajectory, daily life impacts, and emotional concerns.
]]></description>
<dc:creator><![CDATA[ Sanders, G. S., Kumar, I., Dade, A., Bernstein, S. L., Block, C. A., Crowe-Cumella, H., Elwyn, G., Gerraughty, L., Junkins, V., Leyenaar, J. K., Milliman, A., Nano, J. P., O'Hare, A., Ramkumar, N., Sierpe, A., Turner-Gee, Q., Saunders, C. H. ]]></dc:creator>
<dc:date>2026-07-10</dc:date>
<dc:identifier>doi:10.64898/2026.07.05.26356878</dc:identifier>
<dc:title><![CDATA[Normalized barriers and unaddressed concerns: A qualitative study of the lived experiences of adults living in rural areas with advanced chronic kidney disease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-10</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.08.26356008v1?rss=1">
<title>
<![CDATA[
Effects of Ergothioneine Supplementation on Glomerular Filtration and Patient-Reported Urological Symptoms in Adults with Early Renal Function Decline: A Single-Center, Open-Label, Self-Controlled Trial 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.08.26356008v1?rss=1
</link>
<description><![CDATA[
BackgroundEarly renal function decline is often accompanied by bothersome urological symptoms, yet effective early-stage nutritional interventions remain limited. L-Ergothioneine (EGT), a diet-derived antioxidant concentrated in renal tissue via the OCTN1 transporter, has shown renoprotective potential preclinically, but human interventional data are sparse.

MethodsIn this single-center, open-label, self-controlled trial, 31 adults (aged 45-70 years) with early renal function decline and persistent urological symptoms ([&ge;]3 months) received oral EGT (120 mg/day) for 90 days; 27 completed the study. Participants served as their own controls. The primary outcome was the within-subject change in eGFR (CKD-EPI 2021 creatinine); secondary outcomes included cystatin C-based eGFR, serum creatinine, UACR, a 10-item voiding diary, and a low-back-pain visual analogue scale (VAS). Within-subject changes were assessed by paired t-test or Wilcoxon signed-rank test.

ResultsCreatinine-based eGFR increased from 86.04 {+/-} 17.89 to 93.25 {+/-} 19.00 mL/min/1.73 m{superscript 2} (+8.4%; p = 0.0016) and serum creatinine fell by 7.0% (p = 0.015). However, cystatin C-based eGFR and serum cystatin C were unchanged (p = 0.31 and p = 0.99), so the filtration signal was not corroborated by an independent, muscle-mass-independent marker. UACR showed a non-significant downward trend. Patient-reported outcomes improved most robustly: the total voiding diary score decreased by 57.2% (p < 0.0001) and low-back-pain VAS by 67.2% (p = 0.0002), with significant relief of urgency, frequency, and voiding difficulty. No product-related adverse events occurred.

ConclusionsIn this uncontrolled study, 90-day EGT supplementation was associated with marked improvement in urological symptoms and in creatinine-based eGFR, although the latter was not confirmed by cystatin C. These changes cannot be attributed to EGT alone and may substantially reflect placebo and natural-history effects. The findings are hypothesis-generating and warrant confirmation in a randomized, placebo-controlled trial using validated symptom instruments.

Trial RegistrationChiCTR2500108897; Prospectively registered on 2025-09-08.
]]></description>
<dc:creator><![CDATA[ Rong, F., Wu, Z., Xu, Y., Liu, W., Zhou, G., Ding, W., Cao, J., Xiao, G., Xu, D., Zhou, H. ]]></dc:creator>
<dc:date>2026-07-09</dc:date>
<dc:identifier>doi:10.64898/2026.07.08.26356008</dc:identifier>
<dc:title><![CDATA[Effects of Ergothioneine Supplementation on Glomerular Filtration and Patient-Reported Urological Symptoms in Adults with Early Renal Function Decline: A Single-Center, Open-Label, Self-Controlled Trial]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-09</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.25.26356554v1?rss=1">
<title>
<![CDATA[
Urinary CD4+ Effector Memory CD38+ HLA-DR+ T Cells for Diagnosis of Acute Interstitial Nephritis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.25.26356554v1?rss=1
</link>
<description><![CDATA[
IntroductionAcute interstitial nephritis is an important differential diagnosis in patients with deteriorating kidney function. Diagnosis currently requires kidney biopsy, an invasive procedure associated with risks. We hypothesized that urinary T cells may serve as a non-invasive biomarker for acute interstitial nephritis.

MethodsA total of 320 patients undergoing clinically indicated kidney biopsy were enrolled in a discovery cohort at Charite Berlin (n = 80), an internal validation cohort at Charite (n = 100), and an external validation cohort at The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou (n = 140). Urinary immune cells were assessed by flow cytometry. Renal T cell infiltration was evaluated by immunofluorescence in kidney biopsy specimens from the discovery and internal validation cohorts, including 16 patients with acute interstitial nephritis and 9 patients without acute interstitial nephritis. Additionally, CXCL9 was measured by ELISA in 102 urine samples from these cohorts.

ResultsAcross all cohorts, 27 patients (8.4%) were diagnosed with acute interstitial nephritis. In the discovery cohort, multiple urinary T cell subsets were increased in acute interstitial nephritis, with activated CD4+ effector memory T cells expressing CD38 and HLA-DR showing the strongest diagnostic performance. This marker outperformed urinary monocytes, eosinophils, and CXCL9 and was validated in both independent cohorts. Across all cohorts, the area under the receiver operating characteristic curve was 0.84 and increased to 0.91 after exclusion of 8 patients receiving corticosteroids. A cutoff of 211 activated CD4+ effector memory T cells per 100 mL urine yielded a sensitivity of 78% and a specificity of 81%. Urinary activated CD4+ effector memory T cell counts correlated with renal CD4+ and CD4+ CD38+ T cell infiltration in acute interstitial nephritis. Conclusions Urinary activated CD4+ effector memory T cells expressing CD38 and HLA-DR represent a promising non-invasive biomarker for the diagnosis of acute interstitial nephritis.

Lay SummaryAcute interstitial nephritis is a frequent cause of acute kidney injury and is usually diagnosed by kidney biopsy, an invasive procedure that carries risks. We investigated whether immune cells in urine could help identify AIN in a less invasive manner. In this multicenter study, urine samples from 320 patients undergoing kidney biopsy in Germany and China were analyzed. We found that a specific population of activated T cells was markedly increased in the urine of patients with AIN compared with patients with other kidney diseases. This urinary marker outperformed other immune cell types and the inflammatory cytokine CXCL9 and was successfully validated in independent cohorts from both Germany and China. Importantly, urinary activated T cell counts correlated with immune cell infiltration within the kidney. These findings suggest that urinary activated T cells may serve as a non-invasive biomarker to support the diagnosis of AIN and facilitate earlier clinical decision-making.
]]></description>
<dc:creator><![CDATA[ Sha, W., Mirkheshti, P., Feng, S., Skopnik, C. M., Russ, J., Daniel, C., Amann, K., Arzig, J., Goerlich, N., Herrmann, S. M., Klocke, J., Chen, J., Eckardt, K.-U., Jiang, H., Enghard, P. ]]></dc:creator>
<dc:date>2026-07-08</dc:date>
<dc:identifier>doi:10.64898/2026.06.25.26356554</dc:identifier>
<dc:title><![CDATA[Urinary CD4+ Effector Memory CD38+ HLA-DR+ T Cells for Diagnosis of Acute Interstitial Nephritis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-08</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.05.26357308v1?rss=1">
<title>
<![CDATA[
Ketotifen for Moderate-to-Severe Uremic Pruritus in Chronic Dialysis Patients: A Prospective Observational Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.05.26357308v1?rss=1
</link>
<description><![CDATA[
BackgroundUremic pruritus affects up to 90% of individuals and substantially impairs quality of life, in the group of patients undergoing chronic dialysis. Despite multiple therapeutic options, an optimal and well tolerated treatment remains elusive. Ketotifen, a mast cell stabilizer with antihistaminic properties prevent itch by inhibition of mast cell derived tryptase, which modulates protease-activated receptor-2 (PAR-2) in the cowhage itch pathway.

Materials and MethodsIn this prospective observational study, 230 chronic dialysis patients were screened, of whom 48 (20.9%) had clinically significant pruritus identified using a structured questionnaire. Twenty-four patients with moderate-to-severe symptoms who were prescribed ketotifen as part of routine clinical care consented to prospective follow-up. Ketotifen was initiated at 1 mg twice daily, with dose escalation to 2 mg twice daily in patients with persistent symptoms according to routine clinical practice. Pruritus severity was assessed using visual (VAS), verbal (VRS), and numerical (NRS) rating scales before and after treatment.

ResultsAfter two weeks of initial 1mg therapy, 19 showed significant clinical improvement. Mean scores reduced 77.5 [-&gt;] 27.1 (VAS), 87.5 [-&gt;] 20.8 (VRS), and 74.2 [-&gt;] 25 (NRS) (around 65% reduction with p < 0.001 across all scales). Clinical relief was achieved in 83.3% overall and mild tolerable drowsiness occurred only at the 2mg dose.

ConclusionKetotifen is a safe, effective and well tolerated option for moderate to severe uremic pruritus in dialysis patients. Larger multicenter studies are warranted to confirm efficacy and optimize dosing.
]]></description>
<dc:creator><![CDATA[ Mohanraj, K., Deepak Rajiv, A., Krishnaswamy, S. ]]></dc:creator>
<dc:date>2026-07-07</dc:date>
<dc:identifier>doi:10.64898/2026.07.05.26357308</dc:identifier>
<dc:title><![CDATA[Ketotifen for Moderate-to-Severe Uremic Pruritus in Chronic Dialysis Patients: A Prospective Observational Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-07</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.01.26357013v1?rss=1">
<title>
<![CDATA[
Inflammation-based risk score predicts kidney survival in children and adults with chronic kidney disease 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.01.26357013v1?rss=1
</link>
<description><![CDATA[
Chronic kidney disease (CKD) is accompanied by systemic inflammation, but whether inflammatory proteins improve risk stratification beyond kidney function and albuminuria remains unclear. We profiled baseline serum samples from 683 children with CKD in the prospective European 4C study using the Olink Target 96 Inflammation panel and related protein levels to kidney outcomes over 8 years. eGFR and albuminuria were the dominant determinants of the inflammation-related serum proteome. Nonetheless, a four-protein inflammation score (iScore; CD40, CD137, PD-L1 and CX3CL1), defined from protein residuals independent of eGFR and albuminuria, stratified kidney survival and predicted CKD progression beyond established clinical risk factors (adjusted hazard ratio per elevated protein, 1.11; 95% CI, 1.01-1.22). The score showed concordant associations in 2,770 UK Biobank participants with reduced eGFR (adjusted hazard ratio, 1.08; 95% CI, 1.02-1.14). Kidney single-cell transcriptomic analysis mapped these axes to immune-parenchymal communication programs in CKD, supporting inflammation-based risk stratification across the life course.
]]></description>
<dc:creator><![CDATA[ Bartolomaeus, H., Reitmeir, R., Versnjak, J., Hofstetter, J., Behrens, F., Yarritu, A., Bonnekoh, P., Liebau, M. C., Bayazit, A. K., Duzova, A., Canpolat, N., Kaplan Bulut, I., Azukaitis, K., Obrycki, L., Wilck, N., Weitz, M., Zernecke, A., Melk, A., Querfeld, U., Kelm, M., 4C Study Consortium,, Schaefer, F., Holle, J. ]]></dc:creator>
<dc:date>2026-07-02</dc:date>
<dc:identifier>doi:10.64898/2026.07.01.26357013</dc:identifier>
<dc:title><![CDATA[Inflammation-based risk score predicts kidney survival in children and adults with chronic kidney disease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.25.26356635v1?rss=1">
<title>
<![CDATA[
The complexity of anticoagulant prescribing in advanced kidney disease: a case vignette study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.25.26356635v1?rss=1
</link>
<description><![CDATA[
BackgroundAnticoagulants are high-risk medications that require careful consideration of the risks and benefits. In the setting of advanced kidney disease decisions around prescribing anticoagulants is problematic. This relates to a lack of good-quality evidence and the altered renal clearance and protein binding in kidney disease. This leads to prescribing variation and results in patients experiencing different standards of care. The aim of this study was to explore the factors influencing anticoagulant prescribing decisions among nephrology and haematology healthcare professionals in commonly encountered scenarios, in order to better understand variation in prescribing practice.

MethodsThree case-vignettes were presented to 15 haematology and nephrology professionals as part of a semi-structured interview. Participants were purposively selected based on variable responses to a UK anticoagulant prescribing practice survey. An inductive thematic analysis was undertaken as described by Braun and Clark with an iterative review process to identify final themes.

ResultsThere were five main themes that arose from the analysis; evidence, patient factors, knowledge and experience, team influence and systems and they were present across all the three vignettes. The prescribing of anticoagulation in advanced kidney disease is strongly influenced by the knowledge and expertise gleaned by prescribers previous experiences and the incorporation of patient factors. Prescribers commonly seek opinion from senior staff and other members of the multiprofessional team to support their decision making. Decisions are also influenced by organisational factors that are beyond their individual control.

ConclusionDevelopment of guidelines, delivery of education and good-quality evidence is needed to improve prescribing variation and ultimately the quality of care provided to patients with advanced kidney disease.
]]></description>
<dc:creator><![CDATA[ Parker, K., Mitra, S., Thachil, J., Lewis, P. ]]></dc:creator>
<dc:date>2026-06-29</dc:date>
<dc:identifier>doi:10.64898/2026.06.25.26356635</dc:identifier>
<dc:title><![CDATA[The complexity of anticoagulant prescribing in advanced kidney disease: a case vignette study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.26.26356660v1?rss=1">
<title>
<![CDATA[
Deceased-donor kidney transplantation in Brazil, 2014-2024: temporal patterns, regional heterogeneity, and donation-context indicators. 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.26.26356660v1?rss=1
</link>
<description><![CDATA[
BackgroundDeceased-donor kidney transplantation is a component of the Brazilian transplant system and takes place within a deceased-donation environment that includes donor identification, notification, family approach and authorization, organ allocation, and logistics. This study described temporal, macroregional, and federative unit-level variation in deceased-donor kidney transplantation in Brazil from 2014 to 2024, together with hospitalization-based indicators and contextual indicators of the deceased-donation environment.

MethodsThis nationwide descriptive time-series study used publicly available secondary data from the Hospital Information System of the Unified Health System (SIH/SUS), the Brazilian Transplant Registry (RBT/ABTO), and the Brazilian National Transplant System (SNT). Indicators included the number of transplants, transplant rates per million population, kidney transplant waiting list stock, mean length of hospital stay, in-hospital mortality, potential donor notifications, and family interview and refusal proportions. The three databases were analyzed separately and in parallel, without linkage.

ResultsThe annual number of deceased-donor kidney transplants increased over the study period. The kidney transplant waiting list stock also increased. Mean length of hospital stay decreased, and in-hospital mortality decreased over time. Marked macroregional and federative unit-level heterogeneity was observed in transplant activity, hospitalization-based indicators, and contextual indicators of the deceased-donation environment.

ConclusionsDeceased-donor kidney transplantation increased in Brazil between 2014 and 2024, although regional disparities persisted. These findings support monitoring strategies that incorporate contextual indicators alongside measures of transplant activity. Because this was a descriptive study based on secondary data from distinct sources, the findings should not be interpreted as evidence of causal relationships.
]]></description>
<dc:creator><![CDATA[ Convento, M. B., Borges, F. T. ]]></dc:creator>
<dc:date>2026-06-29</dc:date>
<dc:identifier>doi:10.64898/2026.06.26.26356660</dc:identifier>
<dc:title><![CDATA[Deceased-donor kidney transplantation in Brazil, 2014-2024: temporal patterns, regional heterogeneity, and donation-context indicators.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.25.26356529v1?rss=1">
<title>
<![CDATA[
A feasibility study of BEhavioural ACtivation for Haemodialysis: The BEACH Study protocol. 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.25.26356529v1?rss=1
</link>
<description><![CDATA[
IntroductionPeople with kidney failure receiving haemodialysis experience significantly high rates of depression. However, there is a lack of evidence on how to treat depression in this population. A significant barrier to effective treatment is the high treatment burden of haemodialysis, which makes additional appointments prohibitive. Behavioural activation (BA) is an evidence-based brief therapy for depression that has been delivered in a variety of different clinical settings. However, it has not previously been evaluated in the haemodialysis setting.

MethodsThis study aims to evaluate the feasibility and acceptability of a cluster randomised controlled trial (cRCT) of intradialytic BA for people with kidney failure. The study consists of three main components: A pilot cRCT, where we will recruit 52 people who are receiving haemodialysis and experiencing symptoms of depression across two sites. Patients will be cluster-randomised to either BA or usual care and will be followed up for three months; a qualitative process evaluation using semi-structured interviews to explore the experiences of patients, healthcare professionals and carers; and a feasibility economic evaluation exploring the feasibility of collecting healthcare resource use data.

ResultsKey findings will include the feasibility of screening and recruiting participants, participant retention, completion of clinical outcome measures, and the acceptability of the intervention.

ConclusionIf feasible, the next step will be to conduct a definitive, adequately powered cRCT to determine the effectiveness of the intervention in this population, so that we can improve the identification and management of depression for people with kidney failure.
]]></description>
<dc:creator><![CDATA[ Carswell, C., Metcalfe, S., Agyekum, R., Awan, F., Bhandari, S., Bramham, K., Chilcot, J., Millar, J., Gega, L. ]]></dc:creator>
<dc:date>2026-06-29</dc:date>
<dc:identifier>doi:10.64898/2026.06.25.26356529</dc:identifier>
<dc:title><![CDATA[A feasibility study of BEhavioural ACtivation for Haemodialysis: The BEACH Study protocol.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.23.26356313v1?rss=1">
<title>
<![CDATA[
Clinical phenotype of familial hypertensive nephropathy 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.23.26356313v1?rss=1
</link>
<description><![CDATA[
Familial kidney disease is common in Cyprus. Patients with a glomerular phenotype are most likely to have an autosomal dominant variant in collagen type IV alpha 3 chain (COL4A3) or collagen type IV alpha 4 chain (COL4A4) genes but pathogenic variants are not found in the majority of families. We compare the clinical phenotype between two groups of 10 Turkish Cypriot families who lack a pathogenic variant of COL4A3 or COL4A4 but have either the COL4A4 variant p.G545A or p.G999E. Both groups had identical clinical phenotypes with microscopic haematuria detected at least once in 76% of affected family members; urine protein was less than 1 g/day until glomerular filtration rate (GFR) was <30 ml/min. End-stage kidney disease (ESKD) occurred in 24.1% of those over 50 at a median age of 62.8 (36-86) years. Although the genetic cause of renal injury in this large group is still unknown, these families present with a clinical phenotype best characterised as familial hypertensive nephropathy. We propose that this condition accounts for the great excess of renal failure in the Eastern Mediterranean in those over 65 years of age.
]]></description>
<dc:creator><![CDATA[ Neild, G., Oygar, D. D., Behlul, A., Atac, S., Yukselis, M., Ozadali, S., Ozdemir, F., Kazan, H. H., Gale, D. P., Gurkan, C. ]]></dc:creator>
<dc:date>2026-06-26</dc:date>
<dc:identifier>doi:10.64898/2026.06.23.26356313</dc:identifier>
<dc:title><![CDATA[Clinical phenotype of familial hypertensive nephropathy]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-26</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.21.26356128v1?rss=1">
<title>
<![CDATA[
Development and Validation of Machine Learning Models for Predicting Initiation of Emergency Dialysis in Advanced Chronic Kidney Disease 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.21.26356128v1?rss=1
</link>
<description><![CDATA[
BackgroundInitiation of emergency dialysis, often requiring temporary catheter owing to unprepared definitive vascular access, is associated with infectious and vascular complications and suggests advanced chronic kidney disease (CKD) care gaps. Previous studies focused on kidney failure or dialysis timing. This study aimed to predict initiation of emergency dialysis using machine learning and baseline data.

MethodsThis retrospective cohort study used the Japan Medical Data Center claims data (2014-2022). Adults with an estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m2 were included. The primary outcome was initiation of emergency dialysis (temporary catheter code without evidence of previous access preparation). Participants were randomly divided into derivation (80%) and validation (20%) cohorts. Logistic regression, support vector machine, XGBoost, LightGBM, and random forest models were evaluated using internal cross-validation, post-hoc calibration of the selected model, and bootstrap confidence intervals.

ResultsThe cohort included 3,062 individuals (derivation; n=2,449, validation; n=613). Emergency dialysis was initiated in 237 participants (7.7%); 185 (7.6%) and 52 (8.5%) in the derivation and validation cohorts, respectively. Validation area under the receiver operating characteristic curve ranged from 0.781-0.799, with the highest value observed for random forest (0.799, 95% confidence interval; 0.740-0.850). Risk stratification showed clear event enrichment in higher predicted risk categories. SHAP analyses identified hemoglobin, proteinuria, baseline eGFR, diabetes history, and diuretic use as key predictors. Decision curve analysis showed greater net benefit than eGFR alone at lower threshold probabilities.

ConclusionsBaseline machine learning models showed moderate discrimination for initiation of emergency dialysis and identified clinically plausible predictors. These findings support potential use for risk stratification, although external validation and evaluation within pre-specified care pathways are needed before implementation.
]]></description>
<dc:creator><![CDATA[ Hirano, K., Seki, T., Watanabe, A., Kubota, K., Kawazoe, Y. ]]></dc:creator>
<dc:date>2026-06-24</dc:date>
<dc:identifier>doi:10.64898/2026.06.21.26356128</dc:identifier>
<dc:title><![CDATA[Development and Validation of Machine Learning Models for Predicting Initiation of Emergency Dialysis in Advanced Chronic Kidney Disease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-24</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.20.26356118v1?rss=1">
<title>
<![CDATA[
Association between the hemoglobin albumin lymphocyte and platelet score and chronic kidney disease: insights from patient data and animal models 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.20.26356118v1?rss=1
</link>
<description><![CDATA[
IntroductionThe hemoglobin, albumin, lymphocytes and platelets (HALP) score, a novel nutritional and inflammatory biomarker, has been used in various chronic disease studies. However, the relationship between the HALP score and chronic kidney disease (CKD) remains poorly elucidated. This study aimed to explore the possible association between the HALP score and CKD.

MethodsOur analysis encompassed 25,160 adult participants drawn from NHANES cycles spanning 2009 through 2018. Weighted multivariable logistic regression and generalized additive models (GAMs) were employed to evaluate the independent associations between the HALP score and CKD, albuminuria, and low-estimated glomerular filtration rate (eGFR). Threshold effects were examined using two-piecewise linear regression. Subgroup and sensitivity analyses were performed to assess robustness. Receiver operating characteristic (ROC) curve analyses were applied to compare the discriminative capacity of the HALP score with the prognostic nutritional index (PNI), systemic immune-inflammation index (SII), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR). The clinical findings were further validated in a 5/6 nephrectomy rat model.

ResultsAfter adjustment for multiple confounders, higher HALP scores were inversely associated with the risk of CKD (OR = 0.97, 95% CI: 0.94-0.99) and albuminuria (OR = 0.97, 95% CI: 0.93-0.99). However, after full adjustment for demographic characteristics, physical examination indices and laboratory parameters (Model 3), the correlation between the HALP score and low-eGFR was no longer statistically significant. Non-linear analyses revealed a threshold effect, with CKD risk declining as the HALP score increased up to an inflection point of 52.43 (OR = 0.97, 95% CI: 0.95-0.99), beyond which no further protective effect was observed. A similar threshold effect was identified for albuminuria. Subgroup and interaction analyses indicated no meaningful effect modification by age, sex, BMI, hypertension, or diabetes. Sensitivity analyses confirmed the robustness of the results. ROC analysis demonstrated that the HALP score showed superior discriminative ability for CKD and albuminuria compared with PNI, SII, LMR, and PLR. In the animal experiment, CKD model rats exhibited significantly lower HALP scores than controls. Inverse correlations were observed between the HALP score and serum creatinine (Scr), blood urea nitrogen (BUN), and urinary albumin-to-creatinine ratio (UACR), with UACR showing the strongest correlation, which was consistent with the clinical findings.

ConclusionLower HALP scores are independently associated with increased prevalence of CKD and albuminuria. As an affordable and readily measurable biomarker, the HALP score may facilitate CKD risk assessment.
]]></description>
<dc:creator><![CDATA[ Zhang, w., Wang, Y., Ye, W., Wang, Y., Chen, X., Zhao, B., Zhang, X., Chen, z. ]]></dc:creator>
<dc:date>2026-06-23</dc:date>
<dc:identifier>doi:10.64898/2026.06.20.26356118</dc:identifier>
<dc:title><![CDATA[Association between the hemoglobin albumin lymphocyte and platelet score and chronic kidney disease: insights from patient data and animal models]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-23</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.18.26355848v1?rss=1">
<title>
<![CDATA[
Pump-Free Patient-Derived Human Proximal Tubule Microphysiological System for Modeling Flow-Dependent Epithelial Maturation and Cisplatin Injury 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.18.26355848v1?rss=1
</link>
<description><![CDATA[
Recent initiatives by the U.S. Food and Drug Administration and the National Institutes of Health to reduce animal testing in drug development have highlighted the need for in vitro platforms that better recapitulate human biology for preclinical safety assessment. Drug-induced nephrotoxicity remains a major cause of drug attrition, underscoring the need for human-relevant kidney models. To address this, a pump-free human patient-derived proximal tubule microphysiological system was developed by integrating human renal proximal tubular epithelial cells (hRPTECs), isolated from non-tumorous nephrectomy cortex, with a porous membrane-based microfluidic device. Expanded hRPTECs were cultured for 10 days under static conditions or rocker-driven shear stress approximating physiological proximal tubular flow. Shear stress increased epithelial density, enhanced proximal tubule marker expression (Na+/K+-ATPase and aquaporin-1), and improved Zonula occludens-1 and occludin localization. Bulk RNA sequencing demonstrated transcriptomic changes associated with enhanced apical maturation and epithelial signature. In cisplatin-induced injury assays, shear-conditioned epithelia exhibited reduced cell density and increased {gamma}H2AX staining, indicating greater sensitivity to nephrotoxicity. These findings demonstrate that rocker-driven shear stress promotes epithelial maturation in patient-derived hRPTECs. The pump-free human patient-derived proximal tubule microphysiological system offers a practical, scalable, and physiologically relevant platform for modeling flow-dependent proximal tubule biology and assessing human-relevant nephrotoxicity.
]]></description>
<dc:creator><![CDATA[ Sekiguchi, Y., Suzuki, A., Nakao, Y., Hori, T., Mori, M., Mirza, A. F., Shindoh, R., Morita, I., Mandai, S., Fujiki, T., Kikuchi, H., Arai, Y., Ando, F., Susa, K., Mori, T., Waseda, Y., Yoshida, S., Fujii, Y., Sohara, E., Nashimoto, Y., Kaji, H., Mori, Y. ]]></dc:creator>
<dc:date>2026-06-22</dc:date>
<dc:identifier>doi:10.64898/2026.06.18.26355848</dc:identifier>
<dc:title><![CDATA[Pump-Free Patient-Derived Human Proximal Tubule Microphysiological System for Modeling Flow-Dependent Epithelial Maturation and Cisplatin Injury]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-22</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.18.26355937v1?rss=1">
<title>
<![CDATA[
Ten-years absolute risk estimates of death and kidney failure in adults with chronic kidney disease: Analysis of electronic health records of 142,770 patients of the Social Security system of Peru 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.18.26355937v1?rss=1
</link>
<description><![CDATA[
ObjectiveTo determine the absolute risk of starting dialysis versus mortality among adults with chronic kidney disease (CKD) treated at EsSalud from 2013 to 2022, utilizing data from the Renal Health Surveillance system (VISARE).

MethodsThis retrospective cohort study analyzed clinical records from the VISARE system (EsSalud). We estimated rates of dialysis initiation and death using Fine & Gray competitive risk models. Additionally, we calculated Restricted Mean Survival Time (RMST), adjusting for age, sex, clinical stage, and geographic region.

ResultsAmong 142,770 adults with confirmed CKD and available glomerular filtration rate data, only 15.2% had albumin-to-creatinine ratio measurements, allowing KDIGO staging of 40,404 patients (28.3%). Mortality without having previously started dialysis exceeded the probability of starting renal replacement therapy (RRT) from G1, becoming more marked in G3 of chronic kidney disease (CKD); the possibility of dialysis is only greater, as expected, in G5.

This outcome was most prevalent in regions with limited healthcare coverage. The combination of diabetes, hypertension, and age over 55 (the "triad") was associated with reduced restricted mean survival time at both 5- and 10-year horizons across all enrollment cohorts. While Lima saw the highest rates of renal replacement therapy initiation, the Andean and Amazonian regions reported the lowest indicators.

ConclusionsDeath without prior dialysis was the dominant outcome from G1 to G3 in this Peruvian cohort with national insurance, with direct implications for prognostic counseling, recalibration of renal failure risk equations, and equitable expansion of nephrology services in underserved regions.
]]></description>
<dc:creator><![CDATA[ Bravo Zuniga, J., Contreras-Marmolejo, W., Marin-Sanchez, O., Soto -Becerra, P., Coila-Paricahua, E. J., Alamo-Palomino, I., Huanca-Roca, M., Arce-Gallo, L., Loayza-Arroyo, L., Ramos-Quispe, M., Bastidas-Reyes, B., Diaz-Obregon, D. ]]></dc:creator>
<dc:date>2026-06-22</dc:date>
<dc:identifier>doi:10.64898/2026.06.18.26355937</dc:identifier>
<dc:title><![CDATA[Ten-years absolute risk estimates of death and kidney failure in adults with chronic kidney disease: Analysis of electronic health records of 142,770 patients of the Social Security system of Peru]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-22</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.09.26355142v1?rss=1">
<title>
<![CDATA[
A non-invasive liquid biopsy resolves the diagnostic blind spot in chronic kidney disease 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.09.26355142v1?rss=1
</link>
<description><![CDATA[
Chronic kidney disease is a major global health burden, and its early detection is critical for delaying progression to kidney failure using recently developed targeted therapies. However, current diagnostic screening relies heavily on blood markers that are confounded by muscle mass, and on urine tests that frequently miss structural damage occurring without protein leakage. This creates a critical diagnostic blind spot that hinders timely intervention. Here we show a non-invasive liquid biopsy platform that quantifies a specific protein marker, MUC1, on urinary extracellular vesicles to accurately assess renal parenchymal integrity. By bypassing the systemic metabolic noise of traditional blood tests, our assay provides a remarkably stable, person-specific functional signature. Following extensive validation across diverse cohorts, our longitudinal analysis demonstrated that the discrepancy between this novel urine-based readout and standard blood tests unmasks hidden renal vulnerability, successfully predicting rapid functional decline. By comprehensively evaluating both tubular and glomerular integrity from a single spot urine sample, these findings establish a completely non-invasive, highly scalable prescreening tool that resolves the diagnostic blind spot, enabling broader early detection strategies and ushering in a new era of proactive risk management.
]]></description>
<dc:creator><![CDATA[ Nishimura, T., Harita, Y., Hirakawa, Y., Takizawa, K., Fujishiro, J., Ogawa, S., Kajiho, Y., Kanda, S., Kushima, R., Omori, T., Hamasaki, Y., Gotoh, Y., Miura, K., Fujita, N., Okamoto, T., Hisano, M., Nangaku, M., Kato, M. ]]></dc:creator>
<dc:date>2026-06-17</dc:date>
<dc:identifier>doi:10.64898/2026.06.09.26355142</dc:identifier>
<dc:title><![CDATA[A non-invasive liquid biopsy resolves the diagnostic blind spot in chronic kidney disease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.12.26355529v1?rss=1">
<title>
<![CDATA[
Population-scale genomics reveals divergent pathogenicity of variant classes across paralogous collagen IV genes 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.12.26355529v1?rss=1
</link>
<description><![CDATA[
Monoallelic pathogenic or likely pathogenic variants in COL4A3 and COL4A4 occur in approximately 1 in 106 individuals, yet whether these paralogous genes confer equivalent pathogenicity for the same variant classes has not been tested at population scale. Using whole-genome sequencing data from the UK Biobank (UKB; n {approx} 500,000), with replication in the All of Us Research Program (n {approx} 414,000), we performed per-variant association testing, gene-based collapsing analyses and phenome-wide association studies (PheWAS) across haematuria, proteinuria and chronic kidney disease. We identified 64 COL4A3 and 92 COL4A4 rare variants significantly associated with haematuria or proteinuria, generating a quantitative allelic series for clinical variant interpretation. Glycine substitutions within collagenous domains conferred similar risks in both genes. In contrast, truncating and non-collagenous domain (NC1) missense variants were strongly associated with haematuria and proteinuria in COL4A4 carriers but showed substantially attenuated or absent associations in COL4A3 carriers despite comparable carrier frequencies and predicted pathogenicity scores. These findings were independently replicated in All of Us. Genome-wide association analysis identified the COL4A3/COL4A4 locus as the dominant genetic determinant of haematuria, with the signal attributable to the aggregate effects of rare coding variants and no evidence of independent common variant or trans-acting modifier effects. These findings demonstrate substantial gene-specific differences in tolerance to truncating and NC1 variants between COL4A3 and COL4A4, challenging assumptions of equivalent pathogenicity across paralogous collagen IV genes. Gene identity and not variant class alone, should inform risk stratification, variant interpretation and genetic counselling in individuals carrying collagen IV risk genotypes.
]]></description>
<dc:creator><![CDATA[ Tzoumkas, K., Doctor, G. T., Sadeghi-Alavijeh, O., Gale, D. P. ]]></dc:creator>
<dc:date>2026-06-15</dc:date>
<dc:identifier>doi:10.64898/2026.06.12.26355529</dc:identifier>
<dc:title><![CDATA[Population-scale genomics reveals divergent pathogenicity of variant classes across paralogous collagen IV genes]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-15</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.10.26355025v1?rss=1">
<title>
<![CDATA[
Opportunistic CKD Screening in Hospitalized Patients 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.10.26355025v1?rss=1
</link>
<description><![CDATA[
BackgroundChronic kidney disease (CKD) affects 10-13% of adults worldwide but remains largely undiagnosed until advanced stages. Hospitalization provides an opportunity for early detection through opportunistic urine albumin-to-creatinine ratio (UACR) measurement.

MethodsWe conducted a prospective three-arm study of opportunistic CKD screening in general internal medicine wards at Hadassah Mt. Scopus (MS), Hadassah Ein Kerem (EK), and Shaare Zedek Medical Center (SZMC) in Jerusalem (Protocol HMO-23-0300). Adult inpatients without known CKD or recent UACR were enrolled. Pathological UACR was defined as [&ge;]30 mg/g. Confirmed CKD required two pathological measurements [&ge;]90 days apart (KDIGO-compatible). eGFR was computed using the 2021 CKD-EPI race-free equation. Pooled proportions were estimated by fixed-effects logit meta-analysis; odds ratios by DerSimonian-Laird random-effects models.

ResultsA total of 158 patients were enrolled (MS n=50, EK n=57, SZMC n=51). Pathological first UACR was identified in 43/158 patients (27.2%; 95% CI 21.3-34.1%; I2=0% across centers). Of 24 patients with a second UACR available, 14 (58%) confirmed CKD, yielding a pooled confirmed-CKD rate of 8.9% of all screened patients. Short-term mortality was significantly higher among patients with pathological UACR (9.3% vs [~]2%; Fishers exact p=0.012). In per-center multivariate logistic regression, three predictors reached pooled significance: BUN (OR 1.10 per mg/dL, 95% CI 1.04-1.17, p=0.002, I2=0%), heart failure (OR 3.21, 95% CI 1.34-7.70, p=0.009, I2=0%), and diabetes mellitus (OR 2.54, 95% CI 1.11-5.82, p=0.028, I2=17%). Cardiac/vascular admissions had the highest pathological UACR rate ([~]42%); GI/hepatic admissions had 0%.

ConclusionsOpportunistic inpatient UACR screening identifies previously unrecognized CKD in approximately 9% of general internal medicine patients, with consistent results across three independent centers. BUN elevation, heart failure, and diabetes are the strongest independent predictors. Pathological UACR carries significant short-term mortality risk, supporting integration of routine screening into inpatient care pathways.
]]></description>
<dc:creator><![CDATA[ Segal, E., Levy, Y., Ghosheh, M., Wolak, T., Ben-Dov, I. ]]></dc:creator>
<dc:date>2026-06-12</dc:date>
<dc:identifier>doi:10.64898/2026.06.10.26355025</dc:identifier>
<dc:title><![CDATA[Opportunistic CKD Screening in Hospitalized Patients]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.11.26355378v1?rss=1">
<title>
<![CDATA[
Efficacy and safety of SP16 in preventing Acute Kidney Injury in at-risk subjects with chronic kidney disease undergoing elective cardiac surgery using the heart-lung-machine (EASE-AKI): study protocol for a prospective, randomised, double-blind, placebo-controlled clinical trial 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.11.26355378v1?rss=1
</link>
<description><![CDATA[
BackgroundCardiac surgery using cardiopulmonary bypass uses controlled hypoperfusion which leads to relative organ damage. Acute kidney injury is the most frequent and most important organ failure, in particular in patients with chronic kidney disease. To date, there are no approved drug treatments that could effectively prevent acute kidney injury. SP16, an agonist of the low-density lipoprotein receptor-related protein 1, has been shown to exert both reno- and cardioprotective effects in preclinical trials. Early clinical use of SP16 in phase I trials was safe. Administration of SP16 had beneficial trends on inflammatory response and infarct size in patients with ST-segment elevation myocardial infarction. The primary objective of this phase IIa trial is to demonstrate that injection of SP16 is safe and superior to placebo in preventing cardiac surgery-associated acute kidney injury within 7 days after surgery.

MethodsThis randomised, double-blinded, placebo-controlled, single centre study evaluates the efficacy and safety of SP16 in 120 high-risk chronic kidney disease patients with disease stadium G2-G3b undergoing cardiac surgery who are randomised into one of two treatment groups in a 1:1 ratio: SP16 (12 mg) or placebo. The study medication is administered via two subcutaneous injections, with the first dose given before surgery, followed by an additional dose after 9 h. Primary endpoints are the incidence of acute kidney injury during 7 days post-surgery and the frequency of adverse events within 72 h after index surgery. Important secondary endpoints include the incidence of major adverse kidney events at day 90 and impact on cardiac function. Safety assessments encompass adverse events, vital signs, electrocardiograms and routine safety laboratory tests. Additional evaluations include pharmacokinetics and immunological biomarkers.

DiscussionThis single-centre phase IIa trial will assess the incidence of cardiac surgery-associated acute kidney injury, describing the renoprotective potential of SP16 and its safety profile in patients undergoing cardiac surgery.

Trial registrationEUCT, EUCT number 2025-522491-89-00. Registered February 2, 2026, https://euclinicaltrials.eu/ctis-public/view/2025-522491-89-00, Patient recruitment is planned to start April 1, 2026.

Structured summary {1b}
[Table 1][Table 1][Table 1]

Protocol version {3}2026 February 4; version 1.1
]]></description>
<dc:creator><![CDATA[ Jobst-Schwan, T., Bihlmaier, K., Austin, D., Gelber, C., Cesnjevar, R., Harig, F., Schiffer, M. ]]></dc:creator>
<dc:date>2026-06-12</dc:date>
<dc:identifier>doi:10.64898/2026.06.11.26355378</dc:identifier>
<dc:title><![CDATA[Efficacy and safety of SP16 in preventing Acute Kidney Injury in at-risk subjects with chronic kidney disease undergoing elective cardiac surgery using the heart-lung-machine (EASE-AKI): study protocol for a prospective, randomised, double-blind, placebo-controlled clinical trial]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-12</prism:publicationDate>
<prism:section></prism:section>
</item>
</rdf:RDF>
